Stock listing
Oslo:LYTIX Lytix Biopharma ASA Aksje
Home listing (Oslo) of Lytix Biopharma ASA
Follow Lytix Biopharma ASA into a list and get an email when it puts out news.
Share price · OSL:LYTIX
7.80 NOK -0.10 (-1.3%)
Close on Nov 2, 2026
- Day range
- 7.60 – 8.00 NOKNov 2, 2026
- Volume
- 26,167 sharesNov 2, 2026
- Market cap
- 599.8M NOKAt the close on Nov 2, 2026 · price × 76.90M shares outstanding
- 52-week range
- 7.24 – 11.90 NOKLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- 238,294 NOKMedian day 14,398 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Oslo:LYTIX · Home | 7.80 NOK | -0.10 (-1.3%) | 26,167 | 8.00 | 8.00 | 7.60 | 7.90 | Close on Nov 2, 2026 |
| Frankfurt:6BG | €0.716 EUR | -0.012 (-1.6%) | — | €0.716 | €0.716 | €0.716 | €0.728 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · OSL:LYTIX · NOK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 7.80 | -0.10 | -1.3% | 8.00 | 8.00 | 7.60 | 26,167 | |
| 7.90 | +0.16 | +2.1% | 7.58 | 7.98 | 7.56 | 28,440 | |
| 7.74 | +0.24 | +3.2% | 7.50 | 7.88 | 7.50 | 5,212 | |
| 7.50 | -0.38 | -4.8% | 8.00 | 8.00 | 7.50 | 32,465 | |
| 7.88 | +0.02 | +0.3% | 8.00 | 8.00 | 7.70 | 19,694 | |
| 7.86 | -0.10 | -1.3% | 7.76 | 7.92 | 7.76 | 17,611 | |
| 7.96 | 0.00 | 0.0% | 8.20 | 8.20 | 7.80 | 6,869 | |
| 7.96 | +0.06 | +0.8% | 7.98 | 7.98 | 7.70 | 4,493 | |
| 7.90 | -0.18 | -2.2% | 8.50 | 8.50 | 7.74 | 14,788 | |
| 8.08 | +0.10 | +1.3% | 8.08 | 8.08 | 8.08 | 1,150 | |
| 7.98 | -0.02 | -0.2% | 8.48 | 8.48 | 7.98 | 4,948 | |
| 8.00 | +0.20 | +2.6% | 7.80 | 8.10 | 7.80 | 10,297 | |
| 7.80 | -0.10 | -1.3% | 8.00 | 8.00 | 7.72 | 15,370 | |
| 7.90 | -0.12 | -1.5% | 8.50 | 8.50 | 7.80 | 49,306 | |
| 8.02 | 0.00 | 0.0% | 8.30 | 8.30 | 8.02 | 2,957 | |
| 8.02 | -0.18 | -2.2% | 8.02 | 8.28 | 8.02 | 5,654 | |
| 8.20 | -0.04 | -0.5% | 8.00 | 8.22 | 8.00 | 18,040 | |
| 8.24 | -0.24 | -2.8% | 8.24 | 8.40 | 8.10 | 11,259 | |
| 8.48 | +0.24 | +2.9% | 8.60 | 8.60 | 8.00 | 30,404 | |
| 8.24 | -0.10 | -1.2% | 8.26 | 8.60 | 8.22 | 7,069 | |
| 8.34 | +0.06 | +0.7% | 8.78 | 8.78 | 8.20 | 5,043 | |
| 8.28 | +0.02 | +0.2% | 8.00 | 8.28 | 8.00 | 13,494 | |
| 8.26 | -0.50 | -5.7% | 8.78 | 8.78 | 8.04 | 12,037 | |
| 8.76 | +0.26 | +3.1% | 8.60 | 8.78 | 8.60 | 8,380 | |
| 8.50 | -0.08 | -0.9% | 8.50 | 8.50 | 8.34 | 4,250 | |
| 8.58 | +0.12 | +1.4% | 8.78 | 8.78 | 8.34 | 3,578 | |
| 8.46 | 0.00 | 0.0% | 8.46 | 8.46 | 8.46 | 244 | |
| 8.46 | -0.04 | -0.5% | 7.62 | 8.46 | 7.62 | 250 | |
| 8.50 | -0.02 | -0.2% | 8.50 | 8.50 | 8.24 | 7,473 | |
| 8.52 | +0.12 | +1.4% | 8.50 | 9.02 | 8.50 | 20,512 | |
| 8.40 | 0.00 | 0.0% | 8.40 | 8.60 | 8.40 | 6,625 | |
| 8.40 | -0.06 | -0.7% | 8.04 | 8.60 | 8.04 | 11,321 | |
| 8.46 | -0.04 | -0.5% | 8.30 | 8.48 | 8.28 | 4,695 | |
| 8.50 | 0.00 | 0.0% | 8.32 | 8.50 | 8.32 | 18,387 | |
| 8.50 | +0.12 | +1.4% | 8.36 | 8.64 | 8.36 | 50,977 | |
| 8.38 | -0.02 | -0.2% | 8.76 | 8.78 | 8.00 | 60,950 | |
| 8.40 | +0.20 | +2.4% | 8.50 | 8.50 | 8.20 | 4,416 | |
| 8.20 | +0.06 | +0.7% | 8.20 | 8.34 | 8.04 | 8,839 | |
| 8.14 | -0.42 | -4.9% | 8.70 | 8.70 | 8.12 | 21,345 | |
| 8.56 | +0.54 | +6.7% | 8.88 | 8.88 | 8.34 | 11,157 | |
| 8.02 | -0.08 | -1.0% | 8.54 | 8.80 | 8.02 | 98,916 | |
| 8.10 | -0.30 | -3.6% | 8.98 | 8.98 | 8.02 | 67,263 | |
| 8.40 | +0.10 | +1.2% | 9.00 | 9.00 | 7.94 | 16,993 | |
| 8.30 | +0.10 | +1.2% | 8.18 | 8.40 | 7.92 | 37,893 | |
| 8.20 | -0.10 | -1.2% | 8.30 | 8.30 | 7.88 | 14,007 | |
| 8.30 | -0.02 | -0.2% | 8.72 | 9.00 | 8.30 | 48,275 | |
| 8.32 | +0.36 | +4.5% | 8.00 | 8.34 | 7.60 | 48,176 | |
| 7.96 | +0.10 | +1.3% | 8.46 | 8.50 | 7.92 | 59,785 | |
| 7.86 | +0.08 | +1.0% | 7.98 | 7.98 | 7.70 | 12,893 | |
| 7.78 | +0.08 | +1.0% | 7.98 | 7.98 | 7.50 | 2,500 | |
| 7.70 | +0.20 | +2.7% | 7.70 | 7.70 | 7.70 | 2,102 | |
| 7.50 | 0.00 | 0.0% | 7.66 | 7.78 | 7.36 | 10,642 | |
| 7.50 | -0.28 | -3.6% | 8.00 | 8.00 | 7.50 | 48,994 | |
| 7.78 | +0.02 | +0.3% | 8.00 | 8.00 | 7.48 | 26,097 | |
| 7.76 | -0.24 | -3.0% | 7.98 | 8.00 | 7.62 | 45,854 | |
| 8.00 | +0.22 | +2.8% | 7.78 | 8.02 | 7.58 | 8,824 | |
| 7.78 | -0.26 | -3.2% | 8.00 | 8.00 | 7.24 | 123,862 | |
| 8.04 | -0.04 | -0.5% | 8.02 | 8.24 | 8.00 | 59,974 | |
| 8.08 | -0.02 | -0.2% | 8.40 | 8.40 | 8.00 | 21,616 | |
| 8.10 | +0.52 | +6.9% | 7.60 | 8.10 | 7.48 | 37,759 | |
| 7.58 | -0.92 | -10.8% | 8.24 | 8.24 | 7.40 | 197,466 | |
| 8.50 | +0.10 | +1.2% | 8.50 | 8.50 | 8.08 | 232,429 | |
| 8.40 | -0.10 | -1.2% | 8.50 | 8.50 | 8.20 | 4,839 | |
| 8.50 | +0.08 | +1.0% | 8.22 | 8.68 | 8.06 | 89,674 | |
| 8.42 | -0.08 | -0.9% | 8.22 | 8.78 | 8.22 | 29,022 | |
| 8.50 | -0.20 | -2.3% | 8.52 | 8.70 | 8.22 | 11,131 |
- Ticker
- Oslo:LYTIX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Oslo
- Currency
- NOK
What changed lately
Latest news release · Aug 18, 2026
Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
Latest deck · May 21, 2026
Q1 2026 Earnings Presentation
Earnings · 33 slides
Latest news
Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
Aug 18, 2026
Closed 7.76 (-3.0%) on Aug 18, 2026
Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab
Jun 1, 2026
Closed 9.90 (-6.2%) on Jun 1, 2026
Financial Document (2026 Q1 Lytix Biopharma Quarterly Presentation Final)
May 21, 2026
Closed 10.80 (+4.9%) on May 21, 2026
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
May 21, 2026
Closed 10.80 (+4.9%) on May 21, 2026
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026
Apr 21, 2026
Closed 9.90 (0.0%) on Apr 22, 2026
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma
Apr 21, 2026
Closed 9.90 (-4.3%) on Apr 21, 2026
Conversion to public limited liability company and name change registered
Apr 16, 2026
Closed 10.40 (+1.5%) on Apr 17, 2026
Lytix Biopharma ASA - Conversion to public limited liability company and name change registered
Apr 16, 2026
Closed 10.40 (+1.5%) on Apr 17, 2026
Lytix Biopharma AS: Minutes from Annual General Meeting
Apr 14, 2026
Closed 10.20 (-1.9%) on Apr 15, 2026
Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS
Apr 9, 2026
Closed 10.75 (+3.9%) on Apr 10, 2026
Decks
Q1 2026 Earnings Presentation
Earnings · 33 slides · May 21, 2026
Q2 2024 Earnings Presentation
Earnings · 33 slides · Aug 29, 2024
Q2 2023 Earnings Presentation
Earnings · 23 slides · Aug 31, 2023
Q4 2022 Earnings Presentation
Earnings · 26 slides · Feb 16, 2023
Lytix Biopharma ASA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 21 in all · newest Aug 18, 2026 · oldest 2025
- Decks
- 8 decks · latest May 21, 2026
Where Lytix Biopharma ASA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Oslo:LYTIX · Home listing · This page | Oslo | Norway | NOK |
| Frankfurt:6BG | Frankfurt | Germany | EUR |
| Stuttgart:6BG | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Lytix Biopharma ASA.